Moderna Inc
Change company Symbol lookup
Select an option...
MRNA Moderna Inc
FSHOX Fidelity® Select Construction & Housing Portfolio
HRTX Heron Therapeutics Inc
IFBD Infobird Co Ltd
JACK Jack in the Box Inc
MVLY Mission Valley Bancorp
CLSD Clearside Biomedical Inc
GBRGU Goldenbridge Acquisition Ltd
CHMI-B Cherry Hill Mortgage Investment Corp
KAIIU Kismet Acquisition Two Corp
Go

Health Care : Biotechnology | Large Cap Value
Company profile

Moderna, Inc. is a biotechnology company that is focused on creating a transformative medicines based on messenger ribonucleic acid (mRNA), to improve the lives of patients. The Company’s mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a range of spectrum of diseases. It is developing vaccines and therapeutics for infectious diseases, immuno-oncology, rare diseases, autoimmune and cardiovascular diseases, independently and with its strategic collaborators. The Company develops technologies that enable the development of mRNA medicines for diverse applications. It has created modalities, including prophylactic vaccines, systemic secreted and cell surface therapeutics, cancer vaccines, intratumoral immuno-oncology, and systemic intracellular therapeutics. The Company develops technologies that enable the development of mRNA medicines.

Closing Price
$123.64
Day's Change
-0.68 (-0.55%)
Bid
--
Ask
--
B/A Size
--
Day's High
125.01
Day's Low
121.25
Volume
(Light)
Volume:
3,942,637

10-day average volume:
5,723,584
3,942,637

Company Profile

Moderna, Inc. is a biotechnology company that is focused on creating a transformative medicines based on messenger ribonucleic acid (mRNA), to improve the lives of patients. The Company’s mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a range of spectrum of diseases. It is developing vaccines and therapeutics for infectious diseases, immuno-oncology, rare diseases, autoimmune and cardiovascular diseases, independently and with its strategic collaborators. The Company develops technologies that enable the development of mRNA medicines for diverse applications. It has created modalities, including prophylactic vaccines, systemic secreted and cell surface therapeutics, cancer vaccines, intratumoral immuno-oncology, and systemic intracellular therapeutics. The Company develops technologies that enable the development of mRNA medicines.

Valuation Ratios

Price/Earnings (TTM)
3.77x
Price/Sales (TTM)
2.10x
Price/Book (MRQ)
2.69x
Price/Cash Flow (TTM)
3.37x
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

Annual growth, past 5 years
EPS
Revenue
Dividend No Regular Dividend is paid
 

Short Interest

August 2022
Current Month
15.2M
Previous Month
15.0M
Percent of Float
4.30%
Days to Cover
3.4891 Days

Share Information

MRNA is in a share class of common stock
Float
353.8M
Shares Outstanding
391.2M
Institutions Holding Shares
1,414
62.42%

Financial Statements

Balance sheet

Values displayed are in millions.

Income statement

Values displayed are in millions.

Cash flow

No cash flow information available.

Company Officers

  • Noubar B. Afeyan
  • Stephen HogePres.
  • Stephane BancelCEO
  • James M. MockCFO
  • Tracey Franklin

Address

Insider Trading

During the most recent quarter, 2M shares were sold in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.